MINNEAPOLIS, Oct. 6, 2015 /PRNewswire/ -- Verde Technologies,
which develops research-based, scientifically proven solutions to
reduce drug abuse, misuse and negative environmental impact, today
announced the appointment of two new members to its Board of
Directors. Sara Ratner, senior vice
president of operations at RedBrick Health, and Matt Yordy, senior vice president of strategy
and development at McKesson, will join the board effective
immediately.
Ratner brings more than 10 years of experience in healthcare
executive leadership roles. She joined RedBrick Health in 2013 and
currently oversees clinical operations, which includes telephonic
coaching, guide services and biometric screening services.
Previously, Ratner was president of NeoPath Health, executive
sponsor of Medicaid at Prime Therapeutics and led teams at both
CVS-Caremark/MinuteClinic and Fiserv Health. She was named a "Woman
to Watch" in 2009 and a "Top 40 Under 40" in 2012 by the
Minneapolis/St. Paul Business Journal and was included in
the "Real Power 50" list by Minnesota Business Magazine in
2015. She completed her undergraduate studies at Washington University in St. Louis, Mo. and earned a law degree from
St. Louis University.
Yordy is an accomplished corporate strategy and business
development executive with more than 20 years of leadership
experience in the healthcare and insurance industries. At McKesson,
where he oversees the company's annual and long-term strategic
ventures as the senior vice president of strategy and development,
Yordy also serves as a member of the Specialty Health Leadership
Team. Prior to joining McKesson, he ran a private strategic
advisory firm and supported clients' corporate strategy,
organizational structure and executive team alignment. He also
served as senior vice president and chief strategy officer for
Prime Therapeutics. Yordy completed his undergraduate degree in
economics and finance at Creighton
University in Omaha, Neb.
He earned his MBA from Queens University in
Charlotte, N.C. and continued his executive education at The
Wharton School at The University of
Pennsylvania.
"We are extremely fortunate to add Sara and Matt's deep
experience and knowledge to the Verde Technologies Board of
Directors," said Jason Sundby, Verde
Technologies chairman and chief executive officer. "Between Sara's
extensive experience in diverse healthcare segments and her ability
to develop business opportunities; and Matt's strong financial
literacy and strategic vision, Verde is in extremely capable hands
as we grow the business more rapidly than ever before."
Verde Technologies developed and distributes the Deterra Drug
Deactivation System, which utilizes patented MAT12™
Molecular Adsorption Technology to deactivate unwanted, unneeded
narcotics, antibiotics, transdermal patches and other prescription
drugs, rendering them ineffective for misuse and safe for the
environment.
About Verde Environmental Technologies,
Inc.
Minneapolis-based
Verde Environmental Technologies, Inc., is a privately owned
company committed to developing research-based, scientifically
proven solutions to reduce drug abuse and misuse. Originally
introduced as Medsaway, the new Deterra Drug Deactivation System is
powered by patented MAT12 Molecular Adsorption
Technology, which deactivates prescription drugs using proprietary
activated carbon. The technology is highly effective in adsorbing
and firmly binding pharmaceuticals, rendering them inactive and
ineffective for misuse and safe for the environment. For more
information, please visit www.DeterraSystem.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/verde-technologies-appoints-two-new-members-to-board-of-directors-300154962.html
SOURCE Verde Technologies